Delhi Medical College’s medicine dept violates NMC rules, lacks regular or contractual faculty

In a shocking revelation in response to a Right to Information (RTI) application, Delhi-based Dr Babasaheb Ambedkar Medical College’s Medicine Department has neither regular nor contractual faculties.

The said RTI application was filed by a medical student seeking the details of a separate list of contractual and permanent faculty currently working as of date 29.10.2024 in the Department of Medicine at BSA Medical College.

For more information, click on the link below:

Powered by WPeMatico

Fact Check: Sidhu’s video claiming neem leaves, turmeric, apple vinegar, lemon vinegar and intermittent fasting can cure cancer is false and misleading

A viral video on Instagram in which Navjot Singh Sidhu, a former cricketer is seen claiming that neem leaves, turmeric, apple vinegar, lemon vinegar and intermittent fasting can cure cancer is false and Misleading.

Claim

In a viral Instagram reel, Navjot Singh Sidhu is seen claiming that neem leaves, turmeric , apple and lemon vingear can cure cancer. He further claims that if you stop giving food to your body, cancer cells start dying off naturally. The reel is posted by trolls_official and Singh says, “I really feel proud because Noni, has been declared clinically cancer-free. A friend’s son, who is an oncologist from the U.S., told me there was no chance. But I had done my research and identified the common denominators. I told my daughter, “We will start this and you won’t believe it—this press conference is the biggest testament to that.”

As per the post, the former cricketer is stating it was stage 4 cancer with metastasis, and doctors had given a mere 3% chance of survival. Yet, as per him in just 40 days, she bounced back. He further says, “People often say that cancer treatments cost crores, but let me ask you: do neem leaves cost anything? Does raw turmeric cost anything? Do lemon and vinegar cost anything? I will talk about she came back and the diet we gave her.”

He continues to say, “The key is to leave gaps between meals, avoid sugar, and cut down on carbohydrates. If you stop giving these to your body, cancer cells start dying off naturally. We ensured the last meal was eaten before sunset, around 6:00–6:30 PM, and didn’t eat anything again until the next morning at 10:00 AM. Then started the day with lemon water, and half an hour later, 10–12 neem leaves were consumed. And all of this cost almost nothing.”

He further says, “I seriously want to tell everyone that from grade 4 stage 4, she came back within 40 days. Believe me, brothers and sisters, cancer can be defeated if you change your lifestyle. The cancer treatment is the same as for fatty liver.”

He also stated in the reel that coconut works like a miracle. As per him, Anyone struggling with weight or other health issues should try this. He says he followed the same diet plan, and my fatty liver completely healed and lost 25 kg people now say he looks much younger. 

Following the press conference, Several media portals reported the claims in the video. Hindustan Times report was titled “Navjot Singh Sidhu shares wife’s strict diet which helped her beat stage 4 cancer: ‘Started day with lemon water’ ” Similarly another report by The Indian Express was titled “How Navjot Kaur Sidhu got cured of Stage 4 cancer” Another report by India TV News was titled, “Navjot Singh Sidhu’s wife defeats Stage-4 cancer by adopting THESE healthy lifestyle habits”

Many more articles are also there on social media, as well as the video also went viral on various social media including Instagram.

The viral reel can be accessed here.

Fact Check

The reel by the user is Misleading. Neem leaves, turmeric and intermittent fasting may help in the treatment and management of cancer but they alone cannot cure cancer.   

It is worth noting that while the reel focuses solely on diet and its potential role in curing cancer, Navjot Singh Sidhu, in his press conference from the reel has been pocked up, stressed the indispensable role of the healthcare system and accessible medical treatments in managing critical illnesses like cancer. He shared his wife’s journey of overcoming Stage 4 cancer, highlighting the significant contribution of government hospitals in her treatment. Sidhu also advocated for a holistic approach to health, emphasizing the importance of a disciplined lifestyle and healthy eating habits as vital complements to medical care.

The detailed press conference video can be accessed here on this link 

Can neem leaves, turmeric, apple vinegar, lemon vinegar and intermittent fasting cure cancer?

While neem, turmeric and intermittent fasting have been explored for their potential health benefits, there is no scientific evidence or medical consensus to support the claim that they cure cancer. It is also important to note that there is no scientific evidence to support the benefits of apple and lemon vinegar in the management of cancer.

There have been, indeed, various scientific studies that have focused on these herbs and ingredients, analyzing their role in the management of cancer. 

Neem extract, a natural and readily available resource, has garnered attention for its potential as a safe and cost-effective agent in anticancer therapy. Fang Hao et. al.’s study concludes that neem extract shows great potential as an affordable and safe anticancer agent. Preclinical findings emphasize its capacity to inhibit tumor proliferation, trigger cell death, suppress angiogenesis, restore redox balance, and strengthen immune responses. Nevertheless, additional research is required to isolate and identify its active components, elucidate its anticancer mechanisms, and confirm its effectiveness through animal studies and clinical trials.

Similarly, an article published in the Journal of Oral Biology and Craniofacial Research highlighted neem’s anticancer properties, showing that its active constituents possess clear preventive and therapeutic potential against oral cancer. However, further research is necessary to fully explore these properties and integrate neem effectively into routine oral cancer management.
Curcumin, a natural compound extracted from turmeric, has garnered significant scientific interest for its potential anticancer properties. A study conducted by Antonio Giordano et. al. revealed that curcumin, a polyphenol derived from turmeric, shows potential in treating various types of cancer. Its anticancer properties are attributed to its ability to influence multiple cell signaling pathways, including growth factors, cytokines, transcription factors, and genes that regulate cell proliferation and programmed cell death (apoptosis). Despite its potential, curcumin’s poor bioavailability and side effects like nausea, diarrhea, headache, and yellow stool limit its therapeutic efficacy, necessitating further human studies and clinical trials to establish its role as an anticancer agent.

Curcumin has also been widely studied for its therapeutic potential and has been shown to improve cancer treatment outcomes by reducing side effects and enhancing patient well-being. A systematic review published in BMC Cancer confirmed that curcumin alleviates the side effects of chemotherapy and radiotherapy, enhancing patients’ quality of life. Several studies have also shown that curcumin increases patient survival time and reduces tumor marker levels.

Intermittent fasting has emerged as a potential strategy to enhance cancer treatment by reducing toxicities and improving patients’ quality of life. Li Sucholeiki et al. investigated the effects of intermittent fasting on toxicities, symptoms, and quality of life in cancer patients undergoing active treatment. The study revealed promising results, suggesting that intermittent fasting not only has anticancer properties but also helps manage treatment-related side effects more effectively.

Similarly, Sagun Tiwari et. al.’s study highlights intermittent fasting as a promising, affordable, and low-risk strategy for cancer prevention and management, primarily due to its influence on metabolic, biochemical, and immunologic pathways. However, its clinical significance in regulating hormonal and inflammatory markers of carcinogenesis remains uncertain, given the limited available research. Despite challenges in dietary modifications, intermittent fasting offers potential as a tumor-agnostic approach with minimal side effects, warranting further investigation.

All the studies categorically point out that ingredients such as neem and turmeric help in the management of cancer as an adjunct to traditional medical therapy On the other hand apple and lemon vinegar lack scientific backing for cancer management.

Further, there is no scientific evidence or medical consensus to back that any of the ingredients can cure cancer or put it back in remission 

Leading Experts Come out with the Warning

In response to the viral statement made by the former cricketer in the reel, several doctors in the medical fraternity have come out calling these statements as misleading and cautioning general public against solely relying on these measures, or abandoning their current medical treatment in favour of these. 

262 Oncologists, present and past from Tata Memorial Hospital collectively released a statement against these measures and calling these claims as false 

“A video of a former cricketer describing his wife’s treatment for her breast cancer has been circulating widely on social media. Parts of the video imply that “starving the cancer by not eating dairy products and sugar”, consuming haldi (turmeric) and neem helped cure her “incurable” cancer. These statements have no high quality evidence to support them. While research is ongoing for some of these products, there is no clinical data currently to recommend their use as anti-cancer agents. We urge the public to not delay their treatment by following unproven remedies, but rather to consult a doctor, preferably a cancer specialist, if they have any symptoms of cancer. Cancer is curable if detected early and proven treatments for cancer include surgery, radiation therapy and chemotherapy,” the official statement from the hospital stated

Medical Dialogues Final Take

Neem leaves, turmeric, and intermittent fasting have been studied for their potential health benefits in cancer treatment and management but, it is crucial to note that there is no scientific evidence to support the effectiveness of apple and lemon vinegar in cancer management. Additionally, while neem leaves, turmeric, and intermittent fasting may assist in the supportive management of cancer, there is no medical consensus or scientific evidence to substantiate the claim that neem leaves, turmeric, apple vinegar, lemon vinegar and intermittent fasting can cure cancer.

Hence, the claim by the user is False and Misleading.

Powered by WPeMatico

Dr NTRUHS To End Web Options for Phase-I PG Medical Admissions Tomorrow

Andhra Pradesh- Through a notification, Dr NTRUHS University of Health Sciences (Dr NTRUHS) has notified regarding the schedule for exercising Web Options for Phase-I of counselling for both In-Service and Non-service candidates for admissions into Competent Authority Quota (CQ) PG Medical Degree/Diploma courses available in the Government and Private Non-Minority and Minority Medical Colleges under Dr NTR UHS and SVIMS, Tirupati for the academic year 2024-25 for the seats available in some colleges.

As per the schedule, the exercise of the web option process has already started, hence, in-service and non-service candidates can exercise the web option from the official website of Dr NTRUHS till tomorrow i.e. 24th November 2024.

UNIVERSITY FEE

Candidates to whom the seat is allotted have to pay Rs.23,600/- for downloading the allotment letter by using an Online payment method such as Debit Card/Credit Card/Internet Banking. However, the University fee and other fees once paid shall not be refunded under any circumstances.

TUITION FEE

The following is the Tuition fee structure for the academic year 2024-25 to be payable for the Competent Authority Quota seats in Private Un-aided Medical Colleges.

S.NO

NAME OF THE COURSE

FEE FOR CATEGORY-A (CQ) SEATS

1

Clinical Degree/Diploma.

Rs. 4,96,800/-

2

Para Clinical Degree/Diploma.

Rs. 1,55,250/-

3

Pre-Clinical Degree/Diploma.

Rs. 70,380/-

Meanwhile, the following candidates are eligible for Exercising web options in Phase-II Counselling-

1 All the candidates who have been allotted a seat in Phase-I and reported.

2 All the candidates who have not been allotted any seat in Phase-I counselling.

3 All candidates who have been allotted a seat in Phase-I but have not reported/not joined at the allotted colleges. However, if a candidate has not joined/reported in the allotted seat of Phase-I then that particular seat shall not be available for that candidate to exercise web options in Phase-II counselling.

The selected candidates shall produce all the Original certificates, pay the Tuition fee, furnish necessary bonds etc., and complete the process of admission. If the candidate does not fulfil the criteria as per regulations to complete the admission process on the specified dates of admission, their admission will be cancelled automatically. The verification of original certificates will be conducted at the time of admission in the respective College and in case of any discrepancy, the Provisional allotment will be cancelled and action will be initiated. If the candidate slides to other colleges (i.e., affiliated colleges of Dr.NTR UHS) during subsequent Phases of counselling the tuition fee will be sent to the slided college by the concerned college where the amount is held.

The categorization of Area and categorization of candidates in relation to area are as follows-

1 CATEGORISATION OF “AREA”.

1

LOCAL in short “L”.

In respect of all respective Local Seats

2

“ANDHRA PRADESH LOCAL” in short “APL”.

In respect of 36% seats in SMC, Vja towards which candidates local to AU and SVU areas are eligible

3

“ANDHRA PRADESH UNRESERVED” in short “APUR”.

In respect of Unreserved seats.

2 CATEGORISATION OF CANDIDATES IN RELATION TO AREA.

S.NO

TYPE OF CANDIDATE IN RELATION TO LOCAL AREA/NON-LOCAL

TYPE OF ELIGIBLE SEATS

1

AU (Andhra University) area.

a) 15% APUR seats in AU & SVU areas.

b) 85% of Local seats in A.U. area.

c) 42% AU seats in SMC, Vja. d) 36% APL seats in SMC, Vja By Merit.

2

SVU (Sri Venkateswara University) area

a) 15% APUR seats in AU & SVU areas.

b) 85% of Local seats in S.V.U. area.

c) 22% SVU seats in SMC, Vja.

d) 36% APL seats in SMC, Vja by Merit.

3

APNL (Andhra Pradesh Non-Local) with AP domicile only

a) 15% APUR seats in AU & SVU areas.

b) 15% APUR seats in SMC, Vja

To view the schedule, click the link below

https://medicaldialogues.in/pdf_upload/dr-ntruhs-to-end-web-options-for-phase-i-pg-medical-counselling-tomorrow-262029.pdf

Powered by WPeMatico

NMC extends deadline for New PG medical courses, Institutes, Increase of seats

The National Medical Commission (NMC) has extended the last date for submission of applications for starting new Post-Graduate Medical Courses in an established medical institution, establishing a new Post-Graduate Medical Institution (standalone PG institute) and increase of seats in existing Post-Graduate medical courses for the Academic Year (AY) 2025-2026.

While previously the last date to receive applications was 17.10.2024, then 08.11.2024 and till today, now MARB has extended it further till 10.12.2024.

For more information, click on the link below:

Powered by WPeMatico

MSN Laboratories Gets CDSCO Panel nod to Manufacture, Market Tolvaptan Tablets 7.5 mg

New Delhi: Considering the published data on efficacy studies of Tolvaptan Tablets 7.5 mg, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to MSN Laboratories to manufacture and market Tolvaptan Tablets 7.5 mg.

However, this approval is subject to the condition that the firm should conduct the Phase IV clinical trial for efficacy.

This came after MSN Laboratories presented the literature on additional efficacy data on Tolvaptan tablets 7.5 mg, approved by the European Medicines Agency (EMA).

Tolvaptan is used to treat hyponatremia (low sodium in the blood) in patients with heart failure or syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan is also used to slow kidney function decline in adults who are at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

Tolvaptan is a selective vasopressin V2-receptor antagonist to slow kidney function decline in patients at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). It is also used to treat hypervolemic and euvolemic hyponatremia.

Tolvaptan is a selective and competitive arginine vasopressin receptor 2 antagonist. Vasopressin acts on the V2 receptors found in the walls of the vasculature and luminal membranes of renal collecting ducts. By blocking V2 receptors in the renal collecting ducts, aquaporins do not insert themselves into the walls, thus preventing water absorption. This action ultimately results in an increase in urine volume, decrease urine osmolality, and increase electrolyte-free water clearance to reduce intravascular volume and an increase in serum sodium levels. Tolvaptan is especially useful for heart failure patients as they have higher serum levels of vasopressin.

At the recent SEC meeting for renal held on 12th November 2024, the expert panel reviewed the literature on additional efficacy data on Tolvaptan tablets presented by MSN Laboratories.

After detailed deliberation, the committee recommended the grant of permission for manufacturing and marketing of Tolvaptan tablets 7.5 mg considering the published data on efficacy studies submitted by the firm, subject to the condition that the firm shall conduct the Phase IV clinical trial for efficacy.

Accordingly, the expert panel suggested that the firm should submit a Phase IV clinical trial (CT) protocol within 3 months from the date of approval to CDSCO for further review by the committee.

Also Read: Sun Pharma Laboratories Gets CDSCO Panel Nod To Manufacture Market Antipsychotic Lumateperone Capsule

Powered by WPeMatico

Health Bulletin 23/ November/ 2024

Here are the top health news for the day:

Delhi Medical College’s medicine dept violates NMC rules, lacks regular or contractual faculty

In a shocking revelation in response to a Right to Information (RTI) application, Delhi-based Dr Babasaheb Ambedkar Medical College’s Medicine Department has neither regular nor contractual faculties.

The said RTI application was filed by a medical student seeking the details of a separate list of contractual and permanent faculty currently working as of date 29.10.2024 in the Department of Medicine at BSA Medical College.

For more information, click on the link below:

Chargesheet filed against MGM Indore dean over alleged corruption in NPA Incentives

The MGM Medical College, Indore is now facing a controversy as the State Government has issued a chargesheet to the Dean of the Institute for alleged corruption in disbursing incentives for non-practicing allowance to doctors. There are also allegations of misappropriating the incentives under the Ayushman Bharat Scheme, TOI has reported.

In a letter directed to Dr Sanjay Dixit on November 18, the Department of Public Health and Medical Education Deputy Secretary Mayank Agrawal has given a 21-day deadline to Dr. Dixit to respond to the charges. In case, Dr. Dixit failed to respond to the charges within the stipulated timeline of 21 days, a departmental inquiry would commence into the matter.

For more information, click on the link below:

NMC extends deadline for New PG Medical Courses, Institutes, Increase of Seats

The National Medical Commission (NMC) has extended the last date for submission of applications for starting new Post-Graduate Medical Courses in an established medical institution, establishing a new Post-Graduate Medical Institution (standalone PG institute) and increase of seats in existing Post-Graduate medical courses for the Academic Year (AY) 2025-2026.

While previously the last date to receive applications was 17.10.2024, then 08.11.2024 and till today, now MARB has extended it further till 10.12.2024.

For more information, click on the link below:

GMERS Ragging death: College submits report to UGC, family questions accused doctors’ integrity

Providing details regarding the horrifying ragging incident where an 18-year-old first-year MBBS student died after allegedly being forced to stand for three hours by his seniors, the authorities of the GMERS Medical College and Hospital, Patna submitted an action taken report (ATR) to the University Grants Commission (UGC) in connection.

In the report, the authorities specified the action taken so far regarding the seniors involved in the case. They shared details about the number of students connected to the ragging incident, the actions taken against them, and the identification of all victims. Furthermore, they updated UGC about their implementation of the anti-ragging regulations and the committee meetings held after the incident.

For more information, click on the link below:

Powered by WPeMatico

Revise protocol for Denosumab 60 mg prefilled syringe solution for injection: CDSCO Panel tells Lupin

New Delhi: In line with the proposal presented by Lupin for conducting phase I study of Denosumab 60 mg prefilled syringe solution for injection (60 mg/mL), the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to revise the protocol with respect to inclusion of subjects in the study, excluding subjects from the study.

This came after the firm presented the proposal to conduct a Phase I study titled “An open label, randomized, single-dose, single-period, three treatment, parallel comparative pharmacokinetic, pharmacodynamic, and immunogenicity study of Lupin’s Denosumab 60 mg prefilled syringe solution for injection (60 mg/mL) with US and EU-approved Prolia (Denosumab) 60 mg solution for injection (60 mg/mL) in pre-filled syringe in healthy, adult, human male subjects” via Protocol No. LBC-P-097-24 dated 09.07.2024.

The expert panel suggested that serum calcium and vitamin D levels should be in a normal range for inclusion of subjects in the study. In addition, the committee stated that patients with histories of osteonecrosis of the jaw should be excluded from the study. Furthermore, the expert panel added that a serial assessment of levels of serum calcium and vitamin D should be done at each visit of the study subject.

Denosumab is a RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts.

Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. In many bone loss conditions, RANKL overwhelms the body’s natural defense against bone destruction. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.

At the recent SEC meeting for analgesics and rheumatology, the expert panel reviewed the proposed Phase I study protocol of Lupin’s Denosumab 60 mg prefilled syringe solution for injection (60 mg/mL).

After detailed deliberation, the committee recommended the firm conduct the Phase I study with the following changes in the protocol:

1. Serum calcium and vitamin D levels should be in the normal range for inclusion of subjects in the study.

2. Patients with history of Osteonecrosis of the jaw should be excluded from the study.

3. Serial assessment of levels of Serum Calcium and Vitamin D should be done at each visit of the study subject.

In accordance with the above, the expert panel suggested that the firm should submit revised protocol to CDSCO for further evaluation.

Powered by WPeMatico

2021 Assam Doctor Assault Case: 12 people sentenced to 10 years of imprisonment

Nagaon: In a significant ruling, a court in Assam’s Hojai district sentenced twelve individuals to 10 years in prison for assaulting a doctor and a nurse who were on duty during the COVID-19 pandemic. 

Doctor Seoj Kumar Senapati and nurse Lalita Bharali, who were on duty at the COVID care centre in Phultoli Model Hospital on June 1, 2021, were attacked by the relatives of a deceased patient.

According to the PTI report, District and Sessions Judge Satya Nath Sarma delivered the verdict after recording the statements of 46 people.

Based on an FIR at Lanka police station, a charge sheet was filed before the court within 28 days of the incident, said Special Public Prosecutor Amarjyoti Saikia.

The accused were booked under various sections of the IPC, the Prevention of Damage Public Property Act and the Medicare Service Institutions (Prevention of Violence and Damage to Property) Act.

Also Read:2 Gynecologists, 3 nurses sentenced to 2-year jail, directed to pay Rs 50k fine, Rs 1 lakh compensation

A total fine of Rs 1 lakh was also imposed on the convicts, Saikia said.

Additionally, the court imposed fines of Rs 85,000 on each of the convicts, failing to pay which they have to undergo imprisonment of another three months, he added, news agency PTI reported.

Director-General of Police GP Singh lauded the investigators and prosecutors in the case.

“In the infamous Doctor Assault case of Udali – Hojai of 2021, the competent court has pronounced 12 accused persons guilty and awarded Imprisonment up to 10 Years. Compliments to entire investigation and prosecution team,” he posted on X.

Medical Dialogues team had earlier reported that in a significant order, the Gauhati High Court has directed the Assam Government to ensure that no weapon or firearms are allowed to be taken inside a hospital with immediate effect. The court further asked the State to submit a detailed report within two weeks on steps taken to ensure that no attacks on doctors and medical staff take place in future.

Also Read:Bhubaneshwar Doctor Couple murder case: 5 persons sentenced to life imprisonment

Powered by WPeMatico

Haryana Govt Doctors criticize additional charges for Civil Surgeons, Promotions delays

Ambala: The Haryana Civil Medical Services (HCMS) Association has submitted a representation to the Additional Chief Secretary (ACS) of the Haryana Health Department, criticizing the government’s policy of imposing additional charges on civil surgeons. The association has also demanded the prompt promotion of doctors.

The association has highlighted the dual
charge assignment and the challenges faced by the Haryana civil medical services
cadre. The association pointed out that civil surgeons are often forced to hold
additional charges of directors and other administrative posts without any extra
remuneration which causes extreme stress and even affects their overall
performance.

The association has requested that timely
promotion measures be taken so that such vacant posts can be filled with eligible people properly. HCMS claimed that presently, 16-17 posts of Civil Surgeons (CS) or Principal Medical Officers (PMOs) are vacant, and there are many eligible doctors awaiting such promotions for a long time.

Talking to medical
dialogues, the president of the Haryana Civil Medical Services Association, Dr
Rajesh Khyalia, stated, “Additional charges and pending promotion of doctor are
the two hurdles that we civil surgeons are facing right now. There is a strong
sense of resentment among members against such an unprecedented and unwarranted
trend of assigning dual responsibility charge of two different hierarchical
posts to a single officer, which eventually further narrows down the
existing scanty promotional avenues in the cadre resulting in stagnation and
thus degrading morale and motivation of the HCMS cadre.”

In a letter submitted to
the ADS of the Haryana Health Department, the association further added, “Holding
dual charges at senior administrative levels will not only overburden the
individual but can also result in compromised attention & efficiency
required for such roles. Civil Surgeon is a pivotal post in the health department, assigning
additional charge of Civil Surgeon to a Director may lead to administrative
delays and operational inefficiencies in managing health services, ultimately
impacting the quality of healthcare delivery in critical regions.”

Earlier this year, the
association members were unsatisfied because some officials who were appointed
to the position of Director of Health Services in the department were once again
assigned the extra responsibilities of civil surgeons in the state. While Dr
Sukhvir Singh, Director of Health Services (Director General, Health Services) Panchkula was given the
additional charge as the Civil Surgeon of Kurukshetra, Dr Virender Yadav was
assigned the charge of Director, MCH O/o National Health Mission, Sector-2,
Panchkula along with the additional charge of Civil Surgeon, Gurugram. Moreover, Dr Brahmadeep was appointed
as Director Mental Health along with the additional charge of civil surgeon at Jhajjar.

“Assigning the additional
responsibility of Civil Surgeon to a Director could cause administrative delays
and operational inefficiencies in managing health services, which could affect
the quality of healthcare delivery in important regions. The post of Civil
Surgeon is important for both the district and the department,” added Dr
Rajesh.

Powered by WPeMatico

RML Hospital Delhi Recruitment: Assistant Professor Post, Check Out Walk In Interview Details Here

New Delhi: The Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital (ABVIMS and RML Hospital Delhi), have announced the vacancies for the post of Assistant Professor on a contract basis in this medical institute.

Dr Ram Manohar Lohia Hospital, formerly known as Willingdon Hospital, was established by the British for their staff and had only 54 beds. After independence, its control was shifted to New Delhi Municipal Committee. In 1954, its control was again transferred to the Central Government of Independent India.

RML Hospital Vacancy Details:

Total no of vacancies: 22

The Vacancies are in the Department of Medicine, Dermatology, ENT, Gastroenterology, Anesthesia, Neonatology, Paediatrics Cardiology, Peadiatric Surgery, Paediatrics, and Physical Medicine, and Rehabilitation.

The date of Walk-In-Interview – 26th, 28th and 29th November 2024.

Venue and Reporting Time:- Room No. 104, 1st Floor, Administrative Block, ABVIMS by 9.30 a.m.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=RML+Hospital&location=&job_sector=all

Eligible Candidates (How to Apply)?

Suitable and willing candidate may report in Room No. 104, 1st Floor. Administrative Block. ABVIMS for walk-in-interview by 9 30 a.m on the aforesaid dates along with duly filled in application form (2 copies of Annexure I), 4 passport size photographs, original and two set of photocopies of relevant documents. No TA/DA is admissible for attending the interview.

No TA/DA is admissible for the interview. Canvassing of any kind will lead to disqualification. Suitable and willing candidates may walk in for interview on the date specified for the interview of the particular specialty along with application in prescribed format along with 4 passport size photographs Candidates should report in the Room No, 104, 1st Floor, Administrative Block, and ABVIMS by 9.00 AM on the aforesaid dates.

The candidates must bring the filled application form (as per Annexure-II) in triplicate (ONE ORIGINAL SET AND TWO SELF ATTESTED COPIES OF ALL DOCUMENTS) and the original certificates at the time of registration/interview.

Also Read:MAMC Delhi Vacancies: Walk In Interview For SR Post, Check All Details Here

Powered by WPeMatico